Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Impact · against what's priced in

Phio Pharmaceuticals provides a timeline for the next phase of PH-762 clinical development, expecting to complete supporting activities by Q1 2027. While the company is engaging investors via a roadshow, the primary value driver is the clarified regulatory and developmental trajectory for its lead candidate.

PHIO+0.20

No priced-in read yet